Engasertib for frequent nosebleeds from HHT
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed HHT diagnosis (based on Curaçao criteria).
- You have frequent nosebleeds that last several minutes (screening score > 4).
- You have anemia, or have gotten iron through an IV or a blood transfusion in the last 6 months.
- No nasal cautery or surgery in the past 6 weeks, no certain blood vessel drugs like bevacizumab or thalidomide in the past 6 weeks, and no unstable tranexamic acid dose.
- No significant heart rhythm problems or uncontrolled skin conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This study uses an echocardiogram (a heart ultrasound) to look for possible heart problems in people with hereditary hemorrhagic telangiectasia (HHT). It will help doctors understand how HHT affects the heart.
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
This study looks at people with Rendu-Osler (hereditary hemorrhagic telangiectasia) who have just started blood-thinning medicines. It aims to understand how antiplatelet and/or anticoagulant therapy affects safety and outcomes soon after starting.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Hear when a new Hereditary Hemorrhagic Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.